Stay updated with breaking news from Eva Schaefer Jansen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 -- Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD sh...
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024...
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed